PTH Substitution Therapy for Chronic Hypoparathyroidism: PTH 1-84 and Palopegteriparatide.

IF 5.3 2区医学 Current Osteoporosis Reports Pub Date : 2025-02-22 DOI:10.1007/s11914-025-00905-6

Andrea Palermo, Anda Mihaela Naciu, Yu Kwang Tay Donovan, Gaia Tabacco, Guido Zavatta

引用次数: 0

Abstract

Purpose of review: to describe and compare the efficacy and safety of the main PTH treatments, namely PTH(1-84) and palopegteriparatide, for the management of hypoparathyroidism.

Recent findings: neither PTH (1-84) nor PTH(1-34) have been shown a clear and consistent favorable impact on the 24 h urinary calcium excretion normalization, while the positive effect on quality of life is still debated. Recently, the Food & Drug Administration and the European Medicines Agency approved palopegteriparatide as the first true replacement therapy for hypoPT management. Palopegteriparatide is a prodrug of PTH(1-34), administered once daily, and designed to provide continuous exposure to released PTH over a 24-h dosing period. According to phase II and phase III studies, palopegteriparatide seems to fill the gaps identified in existing therapies for hypoPT. Palopegteriparatide is the first real replacement therapy for the management of hypoparathyroidism and seems to fill the gaps identified in existing therapies for hypoPT.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

慢性甲状旁腺功能减退的PTH替代疗法：PTH 1-84和palopegteriparide。

综述的目的：描述和比较PTH的主要治疗方法，即PTH（1-84）和palopegteriparide治疗甲状旁腺功能低下的疗效和安全性。最近的研究发现：PTH（1-84）和PTH（1-34）均未显示出对24小时尿钙排泄正常化的明确和一致的有利影响，而对生活质量的积极影响仍存在争议。最近，美国食品和药物管理局和欧洲药品管理局批准palopegteriparatide作为治疗hypoPT的第一个真正的替代疗法。Palopegteriparatide是甲状旁腺激素（PTH）的前药（1-34），每天给药一次，目的是在24小时给药期间持续暴露于释放的甲状旁腺激素。根据II期和III期研究，palopegteriparatide似乎填补了现有治疗hypoPT的空白。Palopegteriparatide是治疗甲状旁腺功能减退症的第一个真正的替代疗法，似乎填补了现有治疗甲状旁腺功能减退症的空白。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Osteoporosis Reports ENDOCRINOLOGY & METABOLISM-

CiteScore

8.40

自引率

2.30%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of osteoporosis. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as current and future therapeutics, epidemiology and pathophysiology, and evaluation and management. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

期刊最新文献

Immune Checkpoint Inhibitors and Bone Health: Mechanisms, Clinical Implications, and Emerging Perspectives on Bone Fragility. Metabolism in Tumour-Induced Bone Disease. Lithium and the Brain-Bone Axis: A Bridge between Osteoporosis and Alzheimer's Disease. Nutrients and Metabolites as Signalling Molecules in Osteoclasts. Transcriptomics in the Study of Bone and Cartilage.